Last kr61.50 SEK
Change Today -2.25 / -3.53%
Volume 103.4K
NVP On Other Exchanges
Symbol
Exchange
Stockholm
OTC US
Frankfurt
As of 11:29 AM 07/24/14 All times are local (Market data is delayed by at least 15 minutes).

neurovive pharmaceutical (NVP) Snapshot

Open
kr63.50
Previous Close
kr63.75
Day High
kr63.50
Day Low
kr61.50
52 Week High
07/15/14 - kr73.50
52 Week Low
12/3/13 - kr14.21
Market Cap
1.7B
Average Volume 10 Days
430.4K
EPS TTM
kr-1.27
Shares Outstanding
27.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NEUROVIVE PHARMACEUTICAL (NVP)

Related News

No related news articles were found.

neurovive pharmaceutical (NVP) Related Businessweek News

No Related Businessweek News Found

neurovive pharmaceutical (NVP) Details

NeuroVive Pharmaceutical AB (publ) researches and develops mitochondrial-protecting pharmaceuticals in Sweden and Hong Kong. Its product portfolio includes CicloMulsion, a drug candidate, which is in Phase III clinical study for reperfusion injury in vasodilation and vasoreinforcement following myocardial infarction; and NeuroSTAT, a drug candidate that is in Phase IIa clinical study for the treatment of traumatic brain injuries. The company is also developing NVP019, an intravenous formulation that is in pre-clinical phase treatment of acute cardiovascular disease and acute brain injury; NVP014 for the treatment of acute ischemic stroke; NVP015, an orphan drug, which is in pre-clinical development phase for the treatment of primary mitochondrial diseases; and NVP018, an oral formulation for the treatment of Hepatitis B and C. It has a collaboration agreement with the Isomerase Therapeutics for the development and commercialization of the cyclophilin-inhibiting molecules. The company was founded in 2000 and is headquartered in Lund, Sweden.

8 Employees
Last Reported Date: 05/9/14
Founded in 2000

neurovive pharmaceutical (NVP) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: kr1.6M
Chief Scientific Officer
Total Annual Compensation: kr188.0K
Compensation as of Fiscal Year 2013.

neurovive pharmaceutical (NVP) Key Developments

NeuroVive Pharmaceutical AB (Publ) Signs New Agreement with Hospices Civils De Lyon

NeuroVive Pharmaceutical AB (publ) is extending its collaboration with Hospices Civils de Lyon and Professor Ovize, which broadens the scope of NeuroVive's cardiovascular business area and creates the right conditions for the company to retain its leading position in mitochondrial medicine. The new collaboration agreement, designated OPeRA (Organ Protection & Replacement Institute), includes pre-clinical research and development programs as well as clinical phase II programs, providing NeuroVive with access to medical technology and patient groups for the evaluation of its drug candidates. NeuroVive began its collaboration with HCL, and the ongoing phase III study in CicloMulsion in Europe, in 2011. Research into CicloMulsion's efficacy beyond the treatment of reperfusion injury following heart attack grew out of the concept of mitochondrial protection in connection with organ injury focusing on heart disease. The OPeRA program has received financial backing from the French government and from several industry players including NeuroVive and covers the period up until 2018. The program encompasses a number of different medical areas and is based on multidisciplinary programs in diabetes, metabolic disorders, transplantation, cardiovascular diseases, inflammatory conditions and infectious diseases. By becoming an industrial partner in the OPeRA program, NeuroVive has secured access to a unique scientific platform in mitochondrial medicine where its already developed cyclophilin inhibitors such as CicloMulsion, and new drug candidates, can be studied in various animal models for efficacy against cardiovascular diseases before being tested in humans. The clinical studies program at HCL plans to study CicloMulsion in several phase II studies with the intention of generating proof of concept, i.e. demonstrating CicloMulsion's efficacy in a smaller patient group before a decision is made to move on to a larger phase II study. A number of phase II studies in CicloMulsion are scheduled in the period up until 2018. The partnership under the OPeRA program not only gives NeuroVive the rights to the projects directly covered by the collaboration with HCL, but also provides access to research findings for potential commercial development across all areas of the program.

Neurovive Reports Consolidated and Company Earnings Results for the First Quarter Ended March 31, 2014

Neurovive reported consolidated and company earnings results for the first quarter ended March 31, 2014. For the period, on consolidated basis, the company’s other operating income was SEK 43,000 against SEK 704,000 a year ago. Loss before tax was SEK 9,877,000 against SEK 4,739,000 a year ago. Diluted loss per share was SEK 0.39 against SEK 0.24 a year ago. Operating loss was SEK 9,860,000 against SEK 4,863,000 a year ago. Loss for the period attributable to parent company shareholders was SEK 9,565,000 against SEK 4,526,000 a year ago. Cash used in operating activities was SEK 17,353,000 against SEK 4,995,000 a year ago. Acquisition of intangible assets was SEK 2,133,000 against SEK 4,463,000 a year ago. The operating loss was affected by increased external expenses, which were SEK 7,717,000. For the period, the company’s other operating income was SEK 43,000 against SEK 704,000 a year ago. Operating loss was SEK 8,890,000 against SEK 4,190,000 a year ago. Loss before tax was SEK 8,838,000 against SEK 4,030,000 a year ago.

NeuroVive Pharmaceutical AB, Special/Extraordinary Shareholders Meeting, Apr 24, 2014

NeuroVive Pharmaceutical AB, Special/Extraordinary Shareholders Meeting, Apr 24, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVP:SS kr61.50 SEK -2.25

NVP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NVP.
View Industry Companies
 

Industry Analysis

NVP

Industry Average

Valuation NVP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 241.4x
Price/Book 11.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 257.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEUROVIVE PHARMACEUTICAL, please visit www.neurovive.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.